, which retained higher metastatic capacity. Interestingly, suppression of TGFb signaling increased TIC numbers. We here describe the existence of distinct populations of CSCs with differing capacities to initiate tumors in the primary or the secondary site. Inhibiting TGFb signaling shifts the balance toward the former, which may have unanticipated implications for the therapeutic use of TGFb/TGFBR1 inhibitors.
INTRODUCTION
The cancer stem cell (CSC) hypothesis proposes that, similarly to what happens in normal tissues, heterogeneity within tumors is the consequence of their hierarchical organization, i.e., that many tumors are organized as a pyramid with CSCs at its apex. In many tumor types such as breast cancer, this subset of cells is known to sustain tumor growth but also, as we and others have shown, to lead metastatic colonization (Malanchi et al., 2012) . The latter is particularly important since over 90% of cancer-related deaths are due to metastatic disease. Experimentally, CSCs are defined as tumor-derived cells that have the exclusive ability to regenerate a tumor upon transplantationwith all its full complexity and heterogeneity. To assess this capacity, typically CSCs are purified from tumors and tested for their tumor-initiating ability in limiting dilution assays. However, the lack of universal CSC markers poses a serious problem in understanding how homogeneous the CSC pool is.
A few years ago, Weinberg's lab proposed that CSCs can be generated from the epithelial-to-mesenchymal transition (EMT) (Mani et al., 2008) , a process that confers motility and invasiveness to cancer cells and therefore is advantageous to metastasis. However, most secondary tumors derived from carcinomas show an epithelial morphology resembling that of the primary tumor. This suggests that metastatic cells may need to undergo a reverse process, the mesenchymal-to-epithelial transition, once they have colonized a secondary organ (Celia-Terrassa et al., 2012; Ocana et al., 2012; Tsai et al., 2012) . Interestingly, the use of different isolation strategies in the same model allowed some researchers to distinguish between two subsets of CSCs according to their mesenchymal features: EMT-CSCs and MET-CSCs (Liu et al., 2014) . Nevertheless, it is not clear whether CSC transition from one state to the other or two different CSC subpopulations exist in a tumor at a given time. Therefore, understanding whether tumor-initiating cells (TICs) are metastatic is essential in the design of rational targeted therapies and more accurate CSC isolation protocols. Since both tumorinitiating and metastatic CSCs need a different set of features to initiate tumors, we aimed at studying whether they are the same cell population. Here, we use the MMTV-PyMT model to identify two subgroups of CSCs and show that transforming growth factor b (TGFb) receptor 1 (TGFBR1)/ALK5 inhibition prevents metastasis but not tumor initiation.
RESULTS

CD90
À ALDH high Cells Are Lineage-Committed CSCs
The ability of cancer cells to form metastasis in the lungs is typically tested in intravenous injections in the tail vein. Using the MMTV-PyMT model, we have previously shown that most of this capacity is retained by Lin À CD24 + CD90 + cells (Malanchi et al., 2012) . However, what is not clear is the extent of the overlap, if any, between metastatic stem cells and primary TICs. The AldeFluor assay, which determines aldehyde dehydrogenase (ALDH) activity, is frequently used to identify cells that possess higher tumor-initiation capacity (Wan et al., 2014 Figure 1A ). To uncouple the effects on primary tumor-and metastasis-initiation capacity, we next performed orthotopic transplantation of Figure 1 . Metastatic Stem Cells versus Tumor-Initiating Cells (A) FACS analyses of MMTV-PyMT fresh tumors. Lin À ALDH high and Lin À ALDH low DAPI-negative singlets were gated and analyzed for the expression of CD24 and CD90 (absolute frequency, n = 4 independent tumors, paired Student's t test). (B) MMTV-PyMT cells from fresh tumors were FACS sorted using the AldeFluor assay, then counted and injected orthotopically in limiting dilution assays in NSG mice. The presence or absence of tumors was evaluated for a maximum of 3 months after injection. Data were analyzed using ELDA Extreme. Figure 1G ). As expected, CD90-depleted tumors show a 19-fold lower metastatic index when compared with CD90-containing tumors ( Figure S1D ). These results indicate that in the MMTV-PyMT model, CD90 À tumor cells are lineage restricted but they harbor a strong TIP, while CD90 + cancer cells retain a high metastatic potential.
CSC Populations Differ in Their Mesenchymal Traits
The mammosphere assay is frequently used to maintain stem cells in vitro and is often regarded as a surrogate for CSC content (Stingl et al., 2006) . Spheres in the MMTVPyMT model are composed of different cell types, including CD24 + CD90 + cells ( Figure 2A 
Inhibition of TGFBR1 Produces More Sphere-Forming Cells
The acquisition of mesenchymal features through the EMT has been linked to the CSC phenotype (Mani et al., 2008 ).
Since we had observed differences in epithelialization between metastatic CSCs and TICs, we next reasoned that blocking EMT might alter the proportions of CSCs in our system. Therefore, we treated MMTV-PyMT cells with a TGFBR1 inhibitor (SB431542). Surprisingly, treating the cells with the small molecule significantly increased sphere formation ( Figure 3A ). The same effects were achieved with the structurally different TGFBR1 inhibitor Ly2157299 ( Figure S3A ). In secondary sphere cultures, the tendency was maintained and the inhibitor still generated more spheres ( Figure 3B ). We observed similar results in other systems such as 4T1 and MMTV-Wnt1 cells (Figures S3B and S3C) . Importantly, we also observed increased sphere formation in two out of three human breast cancer samples treated with SB431542 or Ly2157299 ( Figures S3D-S3F ). Conversely, adding TGFb3 reduced sphere formation in all the models we tested ( Figure S3 ). To investigate potential differences in the sensitivity to the inhibitor, we performed qPCR analyses on FACS-sorted MMTV- Figure 3E ), which is consistent with our previous results. In agreement with EMT causing a loss of TICs, treating the cells with TGFb3 inhibited sphere formation, while this was rescued by addition of SB431542 ( Figures 3F and S3I ). Consistent with these observations, the inhibitor caused a significant 
CD90
À ALDH low cells showed differences in morphology. Scale bars 100 mm. *p < 0.05, **p < 0.01, ****p < 0.0001; n.s., not significant. reduction in mesenchymal traits as seen by immunostaining in attached cultures ( Figure 3G ). Overall, these results indicate that blocking TGFb signaling through TGFBR1 inhibition is sufficient to trigger the expansion of tumorinitiating progenitors in vitro.
TGFb Signaling Inhibition Reduces Metastasis but Not Tumor Initiation
We next produced three inducible short hairpin RNAs (shRNAs) for Tgfbr1 (1,535, 825, and 777, Figure S4A ) to validate our results in vivo. We infected PyMT cells with shTgfbr1 Figure 3 . Inhibition of TGFBR1 Leads to an Increase in the Number of TICs (A) Tumor cells were obtained from fresh MMTV-PyMT tumors, grown overnight in collagen-coated plates, and seeded as spheres (10 4 cells/ well) in the presence of 2 mM SB431542 or dimethyl sulfoxide (DMSO). Spheres were counted 10 days later (n = 164 control and n = 122 SB, for six independent tumors; unpaired Student's t test). Scale bars, 100 mm. (B) Primary spheres were trypsinized, counted, and replated in ultralow-attachment plates. Spheres were counted 10 days later (n = 30 not pretreated and n = 40 pretreated, for three independent experiments; unpaired Student's t test). Scale bars, 100 mm. (C and D) qPCR analysis of Tgfbr1 on FACS-sorted populations of MMTV-PyMT tumors using the CD24CD90 markers (C) or the AldeFluor assay (D) (n = 3 and n = 4 independent tumors, respectively, paired Student's t test). (E) MMTV-PyMT tumors were digested and cells were plated and treated for 48 h with 2 mM SB431542 or DMSO. FACS analyses showed that TGFBR1 inhibition increased the frequency of ALDH high cells (n = 6 independent tumors, paired Student's t test). (F) Tumor cells were obtained from fresh MMTV-PyMT tumors, grown overnight in collagen-coated plates, and seeded as spheres (10 4 cells/ well) in the presence of DMSO, 1 ng/mL TGFb3, or 1 ng/mL TGFb3 and 2 mM SB431542. The number of spheres was determined after 10 days (n = 34 control, n = 20 TGFb3, n = 9 TGFb3+SB, for two independent tumors; one-way ANOVA and Fisher's LSD). Scale bars, 100 mm. (G) Immunofluorescent staining for E-cadherin (CDH1) and a-smooth muscle actin (ACTA2) in cultured PyMT cells treated with 2 mM SB431542 or DMSO for 5 days. Scale bars, 50 mm.
lentiviruses and injected them orthotopically in FVB/N mice. While tumors did not differ in size, we observed a significant reduction in metastasis in those animals with tumors in which we downregulated Tgfbr1 by doxycyclineinduced shRNA expression ( Figures 4A and 4B) . Similar results were obtained using 4T1 cells in BALB/c mice ( Figures  S4B and S4C Figures 4C and 4D, respectively) . Finally, we treated PyMT cells with SB431542 and injected them either via tail vein or orthotopically in limiting dilution assays. Cells that were pretreated showed reduced metastatic ability in lung metastasis assays ( Figure 4E ), but had higher TIP ( Figure 4F , . (E and F) Cells from fresh MMTV-PyMT tumors were plated and pretreated with either 2 mM SB431542 or DMSO for 5 days and thereafter injected via tail vein or othotopically in limiting dilution assays in FVB/N mice. Pretreating the cells with SB431542 resulted in decreased metastatic colonization potential upon tail vein injection (E; n = 4, unpaired Student's t test; scale bars, 500 mm), while orthotopic injection in limiting dilution assays revealed that pretreated cells exhibit higher TIP (F). p < 0.03). Of note, SB431542 does not affect cell viability in vitro ( Figure S4D ). Taken together, these results indicate that TGFb signaling regulates metastatic and tumor-initiating CSC.
DISCUSSION
CSCs are defined as a subset of cells in a tumor, which possess stem cell properties and sustain tumor growth. These properties are inherent to some particular cells within the tumor, but can also be acquired, which reflects a certain degree of cellular plasticity (Batlle and Clevers, 2017) . In agreement with this rather broad definition, different subsets of CSCs have been identified in different tumors including breast (Yeo et al., 2016) . Furthermore, plasticity in the stem cell niche is known to be an important factor regulating transitions to different stem-like states in CSCs (Brooks et al., 2015) . The CSC field suffers from a major drawback, namely the lack of universal markers: they can vary from mouse to human and between different models of the same type of cancer. Ginestier et al. (2007) poor prognosis or is associated with distant metastasis is a matter of debate (Abraham et al., 2005; Mylona et al., 2008; Nogi et al., 2011; Wei et al., 2012) . We here used the MMTV-PyMT model to show that two populations of tumor cells with distinct tumor-initiating abilities coexist within mammary tumors. The first, which we described as retaining most metastatic potential in the tail vein injection assay, has mesenchymal features and is defined as Lin À CD24 + CD90 + (Malanchi et al., 2012 (Bruttel and Wischhusen, 2014) . This issue has been observed by a number of groups and underlines the importance of using syngeneic models in immunocompetent mice (Quintana et al., 2008) . To understand how these subsets of CSCs are controlled, we modulated TGFb signaling and found that it shifts the proportions of these two CSC populations. Not surprisingly, blocking TGFb signaling inhibits the metastatic population and interferes with the metastatic cascade. However, it also triggers the expansion of ALDH high cells, which have a high tumor-initiation capacity. Our results are in contrast to those previously published showing that in pancreatic cancer TGFb inhibition decreases CSC numbers, including sphere-forming cells (Donahue and Dawson, 2011) . However, it is well known that in breast cancer TGFb plays pleiotropic roles that are context dependent and, therefore, this may be one of the reasons explaining the differences observed (David and Massague, 2018; Fang et al., 2013) . Bhola et al. (2013) showed that in combination with paclitaxel, TGFb inhibition decreased the frequency of triplenegative breast cancer TICs. Interestingly, their data indicate that treating SUM159 cells with the small molecule Ly2157299 increased ALDH + cells and sphere formation, both surrogates for TIP, which is in agreement with our results. In a recent work, Beerling et al. (2016) suggested that cellular plasticity uncouples the effects of EMT on CSCs.
Our results show that, in our model, secondary and primary TIP are features not necessarily shared by the same cell type that can be regulated by TGFBR1 inhibition. These data indicate that TGFBR1 inhibitors might exert different effects that are cell and context dependent. These results may have important implications for treatment, since TGFb inhibitors are currently under clinical trials. In particular, it might be relevant for those patients with circulating tumor cells (CTCs). The presence of CTCs in patients with breast cancer is associated with bad prognosis (Cristofanilli et al., 2005) . It was recently shown that metastases can be polyclonal, i.e., arising from multiple clones that seed the secondary site (Cheung et al., 2016) . This is in line with previous results suggesting that CTC clusters are the precursors of polyclonal metastases (Aceto et al., 2014) . Our data suggest the possibility that treatment with TGFb inhibitors might promote the expansion of circulating tumor stem-like cell clusters, and therefore advise caution when using them to treat patients with breast cancer.
EXPERIMENTAL PROCEDURES
Detailed methods for FACS, qPCR, western blot analysis, and cell culture are provided in Supplemental Information.
Mouse Work
MMTV-PyMT (FVB/N) mice were bred and housed in ventilated cages in the OHB mouse husbandry of the University of Fribourg.
For PyMT tumor cell transplantation to the fourth mammary fat pad or tail vein injection experiments, we used NSG and immunocompetent FVB/N mice. The experiments involving 4T1 cell injections were done in immunocompetent BALB/c mice. For limiting dilution experiments, cells were injected in Matrigel/PBS (1:3). All the experimental procedures involving mice were carried out in accordance with the Swiss Animal Welfare Regulations and were previously approved by the Cantonal Veterinary Service of the Canton Fribourg (2017_26_FR).
Statistics
The results were analyzed using GraphPad Prism 7 software. Means were compared with either paired or unpaired Student's t test. In case groups would not pass a normality test (assessed using D'Agostino-Pearson's omnibus normality test), samples were analyzed with the Mann-Whitney non-parametric test. When comparing more than two variables, we performed one-way ANOVA. To isolate differences between groups, we performed Fisher's least significant difference (LSD) test. p values are indicated for each experiment. Limiting dilution assay data were analyzed using ELDA (extreme limiting dilution assay) (Hu and Smyth, 2009 ).
Experiments were done at least in triplicate. Error bars indicate standard deviation. Significant differences between experimental groups are indicated with asterisks in the figures as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/ 10.1016/j.stemcr.2019.05.026. 
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